Matthew Galsky, MD, discusses the significance of the FDA approval of frontline nivolumab plus chemotherapy patients with metastatic urothelial carcinoma.
Bristol-Myers Squibb (BMY) Reports Eight-Year Data for Opdivo Plus Yervoy Continued to Demonstrate Longest Survival Benefit vs Sunitinib streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The Group announces that eight-year data for Opdivo plus Yervoy continue to demonstrate the longest survival benefit over sunitinib reported in patients with previously untreated advanced or.